Jaguar health achieves approximately 75% enrollment in pivotal phase 3 ontarget trial of crofelemer for cancer therapy-related diarrhea

Addition of ontarget trial sites in europe, south america and asia has significantly accelerated enrollment, which is expected to complete in q2 2023 adoption of premier digital health technology for data collection facilitates operational efficiency of this global trial san francisco, ca / accesswire / february 21, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced that patient enrollment has reached approximately 75% in the company's pivotal phase 3 ontarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy, with or without chemotherapy. target trial enrollment of 256 patients is expected to complete in the second quarter of 2023.
JAGX Ratings Summary
JAGX Quant Ranking